Lexicon Pharmaceuticals (NASDAQ:LXRX) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a report published on Wednesday morning.

LXRX has been the topic of a number of other reports. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 23rd. SVB Leerink initiated coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday. They issued an outperform rating and a $5.00 price target on the stock.

Lexicon Pharmaceuticals Trading Up 7.1 %

Shares of Lexicon Pharmaceuticals stock opened at $1.65 on Wednesday. Lexicon Pharmaceuticals has a 12-month low of $0.92 and a 12-month high of $3.79. The company has a market cap of $406.30 million, a price-to-earnings ratio of -2.06 and a beta of 1.27. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07. The company’s 50-day moving average price is $2.13 and its 200-day moving average price is $1.74.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. On average, equities analysts expect that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Cantor Fitzgerald L. P. bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $25,000. Principal Securities Inc. bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $33,000. TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals in the third quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. increased its position in shares of Lexicon Pharmaceuticals by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 22,043 shares during the last quarter. Finally, RPO LLC bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $49,000. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.